$35.16
18.58% yesterday
Nasdaq, Oct 31, 09:02 pm CET
ISIN
US89422G1076
Symbol
TVTX

Travere Therapeutics Inc Stock price

$35.16
+11.26 47.11% 1M
+14.35 68.96% 6M
+17.74 101.84% YTD
+17.66 100.91% 1Y
+13.48 62.18% 3Y
+15.01 74.49% 5Y
+14.16 67.43% 10Y
+34.95 16,885.51% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
+5.51 18.58%
ISIN
US89422G1076
Symbol
TVTX
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.7b
Net debt
$60.3m
Cash
$319.5m
Shares outstanding
89.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.9 | 6.2
EV/Sales
8.1 | 6.3
EV/FCF
negative
P/B
80.7
Financial Health
Equity Ratio
9.9%
Return on Equity
-544.3%
ROCE
-46.7%
ROIC
-90.4%
Debt/Equity
11.6
Financials (TTM | estimate)
Revenue
$333.9m | $429.3m
EBITDA
$-122.1m | $-66.0m
EBIT
$-170.7m | $-101.0m
Net Income
$-169.1m | $-106.1m
Free Cash Flow
$-157.3m
Growth (TTM | estimate)
Revenue
87.9% | 84.1%
EBITDA
56.0% | 69.2%
EBIT
46.0% | 60.6%
Net Income
-15.9% | 67.0%
Free Cash Flow
58.9%
Margin (TTM | estimate)
Gross
96.9%
EBITDA
-36.6% | -15.4%
EBIT
-51.1%
Net
-50.6% | -24.7%
Free Cash Flow
-47.1%
More
EPS
$-1.9
FCF per Share
$-1.8
Short interest
13.4%
Employees
385
Rev per Employee
$610.0k
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Travere Therapeutics Inc forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
334 334
88% 88%
100%
- Direct Costs 10 10
10% 10%
3%
323 323
92% 92%
97%
- Selling and Administrative Expenses 236 236
5% 5%
71%
- Research and Development Expense 210 210
5% 5%
63%
-122 -122
56% 56%
-37%
- Depreciation and Amortization 49 49
24% 24%
15%
EBIT (Operating Income) EBIT -171 -171
46% 46%
-51%
Net Profit -169 -169
16% 16%
-51%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Positive
Investors Business Daily
about 12 hours ago
Travere Therapeutics stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug, Filspari.
Neutral
Seeking Alpha
about 22 hours ago
Travere Therapeutics, Inc. ( TVTX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Nivi Nehra - Vice President of Corporate Communications & Investor Relations Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Chief Research Officer Conference Call Partici...
Neutral
Business Wire
one day ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update. “We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confiden...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 385
Founded 2008
Website travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today